Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE We tested the effects of alisertib or AURKA overexpression or knockdown in 10 upper gastrointestinal or colon cancer cell lines with KRAS mutations or amplifications using the CellTiter-Glo luminescence and clonogenic cell survival assays. 30342037 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE However, TP53 mutations were more prevalent in colon cancer with KRAS mutations than in rectal cancer (75.0% vs 28.6%, respectively, p = 0.004). 31729406 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE We investigated a biomarker of response for MEK inhibition in KRAS mutant colon cancers by LC-MS/MS analysis. 30944457 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE No significant difference between colon cancer and rectal cancer regarding the KRAS status. 30917791 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE The present study is aimed to evaluate the effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of miRNAs 135b, 26b, 18a, and 155 and their target genes, including APC, PTEN, KRAS, and PU.1 in mouse azoxymethane (AOM)-induced colon cancer. 30311185 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE The lack of mutant KRAS-induced effector activation observed in SW48 cells appears to be representative of a broad panel of colon cancer cell lines harboring mutant KRAS. 30785867 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE In addition, we identified a KRAS codon 146 mutation (A146V), which is associated with resistance to anti-EGFR, in a cetuximab-resistant colon cancer patient with wild-type KRAS exons 2 and 12, and EGFR amplification.He received bevacizumab therapy. 30448735 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Rapid discrimination of colon cancer cells with single base mutation in KRAS gene segment using laser tweezers Raman spectroscopy. 30485680 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE The kinetics of ctDNA derived from each cancer type were monitored targeting BRAF V600R (melanoma) and KRAS G13D (colon cancer), specifically reflected the status of the patient's tumours. 31727009 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Here we investigated whether combination of 5-FU and a MEK inhibitor had treatment sequence-dependent synergistic effects in KRAS or BRAF mutant colon cancer models. 30579838 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Our study provides new insights into the mechanisms of resistance to KRAS ablation, and suggests novel strategies for the treatment of KRAS-mutant colon cancers. 30833665 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 AlteredExpression disease BEFREE Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium. 31266962 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE Quest for metabolic inhibitors with anti-tumour activity may constitute a novel and hopeful approach in order to handle KRAS dependent chemoresistance in colon cancer. 30623364 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE NO<sub>2</sub> functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer. 31199928 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE In the present study, it is demonstrated that KRAS and BRAF mutations induce anoikis resistance in colon cancer (Caco‑2) cells. 31545494 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. 29127628 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations. 29498789 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Targeting bioenergetic metabolism with mitochondria-targeted drugs to stimulate mitophagy provides an attractive approach for therapeutic intervention in KRAS WT and overactive mutant-expressing colon cancer. 30087121 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Furthermore, EGF‑ETA was just as potent in HCT116 (KRAS G13D) and SW480 (KRAS G12V) colon cancer cell lines harbouring KRAS hyperactivating mutations when compared to KRAS wild‑type HT29 colon cancer cells. 30226622 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 Biomarker disease BEFREE Collectively, Src can play a key role in apoptosis induced by the novel EGFR inhibitor MHYs, suggesting that activation of Src might prove effective in treating EGFR/wild-type KRAS colon cancer. 30158525 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE We identify the ERN1-JNK-JUN pathway as a novel regulator of MEK inhibitor response in KRAS mutant colon cancer. 30482246 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Together, these results identify that the HSF1-BAG3-Mcl-1 signal axis is critical for protection of mutant KRAS colon cancer cells from AUY922-induced apoptosis, with potential implications for targeting HSF1/BAG3/Mcl-1 to improve the efficacy of AUY922 in the treatment of colon cancer. 29068469 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE Methods The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon cancer in patients who underwent SABR; patients receiving previous chemotherapy alone or in combination with bevacizumab; Karnofsky performance status >80; life expectancy >6 months; at least 6 months' follow-up after SABR; presence of KRAS mutation. 29737958 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE In this study, we assessed and compared the mutational status of KRAS, NRAS, and PIK3CA in PDCs and corresponding main tumor tissue of 25 CCs with KRAS mutations. 28025078 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.500 GeneticVariation disease BEFREE In our study, we successfully identified KRAS mutation in colon cancer patients. 28214514 2017